The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial
Open accessAbstract
Background: Dysregulation of the gut microbiome has been implicated in Parkinson's disease (PD). This study aimed to evaluate the clinical effects and safety of a single faecal microbiota transplantation (FMT) in patients with early-stage PD. Methods: The GUT-PARFECT trial, a single-centre randomised, double-blind, placebo-controlled trial was conducted at Ghent University Hospital between December 01, 2020 and December 12, 2022. Participants (aged 50-65 years, Hoehn and Yahr stage 2) were randomly assigned to receive nasojejunal FMT with either healthy donor stool or their own stool. Computer-generated randomisation was done in a 1:1 ratio through permutated-block scheduling. Treatment allocation was concealed for participants and investigators. The primary outcome measure at 12 months was the change in the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score obtained during off-medication evaluations. Intention-to-treat analysis was performed using a mixed model for repeated measures analysis. This completed trial is registered on ClinicalTrials.gov (NCT03808389). Findings: Between December 2020 and December 2021, FMT procedures were conducted on 46 patients with PD: 22 in the healthy donor group and 24 in the placebo group. Clinical evaluations were performed at baseline, 3, 6, and 12 months post-FMT. Full data analysis was possible for 21 participants in the healthy donor group and 22 in the placebo group. After 12 months, the MDS-UPDRS motor score significantly improved by a mean of 5.8 points (95% CI -11.4 to -0.2) in the healthy donor group and by 2.7 points (-8.3 to 2.9) in the placebo group (p = 0.0235). Adverse events were limited to temporary abdominal discomfort. Interpretation: Our findings suggested a single FMT induced mild, but long-lasting beneficial effects on motor symptoms in patients with early-stage PD. These findings highlight the potential of modulating the gut microbiome as a therapeutic approach and warrant a further exploration of FMT in larger cohorts of patients with PD in various disease stages. Funding: Flemish PD patient organizations (VPL and Parkili), Research Foundation Flanders (FWO), Biocodex Microbiota Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“One study reported no changes in motor function at 6 months post-FMT, although here the treatment group required smaller dose increases than placebo.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [209]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In these studies, the clinical findings were associated with a shift toward anti-inflammatory microbial species.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [209]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three of these reported changes in global or motor function, and of these two reported significant improvement UPDRS PD symptom scores at 12 weeks and 12 months, respectively.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [209]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are currently four RCTs with available evidence for the role of FMT in treating PD [206–209].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [209]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In this study, only 3% of the treatment group were reported to show a change from dysbiotic to non-dysbiotic status, compared to 33% in the placebo arm, suggesting that the FMT treatment failed to produce a significant change in the gut microbiome.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [209]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In this study, only 3% of the treatment group were reported to show a change from dysbiotic to non-dysbiotic status, compared to 33% in the placebo arm, suggesting that the FMT treatment failed to produce a significant change in the gut microbiome.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [209]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397
Inflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Vagotomy and subsequent risk of Parkinson's disease
Svensson, E., Horváth‐Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015) · Annals of Neurology · doi:10.1002/ana.24448 · Cited by 806
Cited by
Sorted by citations
Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial
Scheperjans, F., Levo, R., Bosch, B., Lääperi, M., Pereira, P. A. B., Smolander, O.-P., Aho, V. T. E., Vetkas, N., Toivio, L., Kainulainen, V., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2305 · Cited by 128
Feng, R., Zhu, Q., Wang, A., Wang, H., Wang, J., Chen, P., Zhang, R., Liang, D., Teng, J., Ma, M., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03781-6 · Cited by 49
Microbiome-based therapies for Parkinson’s disease
Alam, M., Abbas, K., Mustafa, M., Usmani, N., & Habib, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1496616 · Cited by 46
Periodontal bacteria influence systemic diseases through the gut microbiota
Xi, M., Ruan, Q., Zhong, S., Li, J., Qi, W., Xie, C., Wang, X., Abuduxiku, N., & Ni, J. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1478362 · Cited by 49
The gut–brain axis in early Parkinson’s disease: from prodrome to prevention
Oliver, P. J., Civitelli, L., & Hu, M. T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13138-5 · Cited by 42
Xie, J., Hoecke, L. V., Wonterghem, E. V., Imschoot, G. V., Andries, V., Vereecke, L., & Vandenbroucke, R. E. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2501193 · Cited by 43
Self-citationThe Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Menozzi, E., Schapira, A. H. V., & Borghammer, P. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70029 · Cited by 42
Liu, Y., Li, X., Chen, Y., Yao, Q., Zhou, J., Wang, X., Meng, Q., Ji, J., Yu, Z., & Chen, X. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1556827 · Cited by 37
Integrative systems biology approaches for analyzing microbiome dysbiosis and species interactions
Rehman, S. S. U., Nasar, M. I., Mesquita, C. S., Khodor, S. A., Notebaart, R. A., Ott, S., Mundra, S., Arasardanam, R. P., Muhammad, K., & Alam, M. T. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf323 · Cited by 35
Taj, T., Kaushik, M., Islam, A., Das, J., Kumar, B., Hussain, M. S., Ramzan, M., Ashique, S., Tariq, M., Sridhar, S. B., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118861 · Cited by 35
Microbiome-based therapeutics for Parkinson's disease
Hamilton, A. M., Krout, I. N., White, A. C., & Sampson, T. R. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00462 · Cited by 31
Gut microbiota and Parkinson’s disease
Wang, L., Cui, Y., Han, B., Du, Y., Salewala, K. S., Wang, S., Zhao, W., Zhang, H., Wang, S., Xu, X., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003318 · Cited by 31
Bedarf, J. R., Romano, S., Heinzmann, S. S., Duncan, A., Τράκα, Μ., Ng, D. Y. K., Segovia-Lizano, D., Simon, M., Narbad, A., Wüllner, U., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00885-5 · Cited by 32
Beyond the Brain: Exploring the multi-organ axes in Parkinson’s disease pathogenesis
Liu, T., Wu, H., & Wei, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.05.034 · Cited by 33
The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease
Fonseca, M. D. C., Zanetti, L., Fanourakis, S., Sulzer, D., & Mazmanian, S. K. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00382-5 · Cited by 29
Yang, H., Shao, Y., Hu, Y., Jin, Q., Wang, P., Tian, L., Ni, Y., Li, S., Al‐Nusaif, M., Liu, C., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70003 · Cited by 33
Ren, J., Wang, Q., Hong, H., & Tang, C. (2025) · Microorganisms · doi:10.3390/microorganisms13081956 · Cited by 28
Eslami, M., Adampour, Z., Dowlat, B. F., Yaghmayee, S., Tabaei, F. M., Oksenych, V., & Naderian, R. (2025) · Biomedicines · doi:10.3390/biomedicines13040915 · Cited by 27
Parkinson's Disease: The Epidemiology, Risk Factors, Molecular Pathogenesis, Prevention, and Therapy
Guo, X., Song, D., Wu, M., Zhang, J., Li, J., & Yuan, L. (2025) · MedComm · doi:10.1002/mco2.70540 · Cited by 31
Wang, J., Xue, L., Zhang, M., Shen, P., Zhao, W., Tong, Q., Wu, S.-N., Dai, W., Yang, X., & Wang, H. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106086 · Cited by 25
Yadav, S., & Raj, R. G. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.003 · Cited by 24
Faecal microbiota transplant in Parkinson’s disease: pilot study to establish safety & tolerability
Sciscio, M. D., Bryant, R. V., Haylock‐Jacobs, S., Day, A. S., Pitchers, W., Iansek, R., Costello, S. P., & Kimber, T. E. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01061-5 · Cited by 24
Kumar, D., Bishnoi, M., Kondepudi, K. K., & Sharma, S. S. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10433-x · Cited by 22
Kaufhold, C. J., Mani, K. K., Akbari, Z., & Sohrabji, F. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.06.026 · Cited by 21
Duan, W.-X., Xie, W.-Y., Ying, C., Fen, W., Cheng, X.-Y., Mao, C.-J., Liu, J., & Liu, C.-F. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01029-5 · Cited by 21
Nabil, Y., Helal, M. M., Qutob, I. A., Dawoud, A. L. A., Allam, S., Haddad, R., Manasrah, G. M., AlEdani, E. M., Sleibi, W., faris, A., et al. (2025) · BMC Neurology · doi:10.1186/s12883-025-04105-8 · Cited by 21
Kerstens, R., & Joyce, P. (2024) · Biomedicines · doi:10.3390/biomedicines12081738 · Cited by 20
The Role of the Gastrointestinal Microbiota in Parkinson’s Disease
Gabrielli, M., Verme, L. Z. D., Zocco, M. A., Nista, E. C., Ojetti, V., & Gasbarrini, A. (2024) · Biomolecules · doi:10.3390/biom15010026 · Cited by 19
Chevalier, C., Tournier, B. B., Marizzoni, M., Park, R., Paquis, A., Ceyzériat, K., Badina, A. M., Lathuilière, A., Saleri, S., Cillis, F. D., et al. (2025) · Genes Brain & Behavior · doi:10.1111/gbb.70012 · Cited by 19
Liu, J., Ge, P., Luo, Y., Sun, Z., Luo, X., Li, H., Pei, B., Xun, L., Zhang, X., Jiang, Y., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s512207 · Cited by 20
How leaky is the gut in Parkinson’s disease?
Derkinderen, P., Cossais, F., Kulcsárová, K., Škorvánek, M., Montaigne, L. S., Coron, E., Leclair‐Visonneau, L., Cerri, S., Pellegrini, C., & Rolli‐Derkinderen, M. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105796 · Cited by 21
Chen, K., Sun, L., Liu, Y., & Chen, R. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1639911 · Cited by 20
Sadowski, K. A., Zając, W., Milanowski, Ł., Koziorowski, D., & Figura, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147741 · Cited by 22
Li, J., Liu, T., Xian, M., Zhou, K., & Wei, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.03.001 · Cited by 20
Modulating biological aging with food-derived signals: a systems and precision nutrition perspective
Carlberg, C., Blüthner, A., Schoeman-Giziakis, I., Oosting, A., & Cocolin, L. (2025) · npj Aging · doi:10.1038/s41514-025-00266-5 · Cited by 17
From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson’s Disease Treatment?
Vilela, C., Araújo, B., Soares-Guedes, C., Caridade-Silva, R., Martins‐Macedo, J., Teixeira, C., Gomes, E. D., Prudêncio, C., Vieira, M., & Teixeira, F. G. (2024) · Cells · doi:10.3390/cells13090770 · Cited by 18
Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease
Zhang, Y., Mo, C., Ai, P., He, X., Xiao, Q., & Yang, X. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2454937 · Cited by 20
The role of the intestinal microbiome in cognitive decline in patients with kidney disease
Wagner, C. A., Frey-Wagner, I. M., Ortíz, A., Unwin, R. J., Liabeuf, S., Suzumoto, Y., Iervolino, A., Stasi, A., Marzo, V. D., Gesualdo, L., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae253 · Cited by 17
Parkinson Disease and the Gut: A Primer for Gastroenterologists
Sharma, A., Voigt, R. M., Goetz, C. G., & Keshavarzian, A. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003508 · Cited by 17
Promoting cognitive health through the nexus of gut microbiota and dietary phytochemicals
Luo, L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1636131 · Cited by 16
Mercado, G., Käufer, C., Richter, F., & Peelaerts, W. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240195 · Cited by 16
Microglia in the crosstalk between peripheral and central nervous systems in Parkinson’s disease
Li, T., Qiu, T., Jiang, F., Cai, H., & Le, W. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00531-3 · Cited by 15
Zhang, R., Feng, R., Wang, J., Chen, Y., Liu, H., Zhu, Q., Tian, H., Qin, C., Teng, J., Tang, B., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02604-9 · Cited by 14
Santos, S., Salinas, I., Almeida, N., & Caicedo, A. (2025) · Engineering Microbiology · doi:10.1016/j.engmic.2025.100222 · Cited by 13
Gut Microbiome as a Source of Probiotic Drugs for Parkinson’s Disease
Poluektova, E. U., Stavrovskaya, A. V., Pavlova, A. K., Yunes, R. А., Марсова, М. В., Koshenko, T. A., Illarioshkin, S. N., & Даниленко, В. Н. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199290 · Cited by 13
Ford, D. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116809 · Cited by 13
Gut–brain axis in health and brain disease
Olasunkanmi, O. I., Zheng, L., & Zheng, P. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003920 · Cited by 12
Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities
Jiang, C., Nageeb, W. M., Batool, S., Hashish, A., Alkhawagah, S. M., Ibrahim, H. A. A., Zhu, W., Che, C., Li, X., Jin, M., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116224 · Cited by 12
Merchak, A. R., Bolen, M. L., Tansey, M. G., & Menees, K. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00476 · Cited by 12
Unlocking the neuroprotective secrets of natural products: a focus on the gut-brain axis
Yang, X., Hu, D., Cheng, R., Bao, Q., Jiang, H., Zhao, B., & Zhang, Y. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10081-1 · Cited by 11
Gut microbiota and sepsis-associated encephalopathy: pathogenesis and precision therapies
Wei, N., Dai, S., Li, W., Zhou, J., & Chen, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1596467 · Cited by 11
The role of the gut microbiota in neuropsychiatric disorders and therapy
Zhang, F., Ding, K., Zhang, L., Liu, D., Dong, X., Wang, M., Zhou, F.-L., Sun, Y., Zhang, W., Yu, Y., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102894 · Cited by 11
Waseem, M. H., Abideen, Z. U., Shoaib, A., Rehman, N., Osama, M., Sajid, B., Ahmad, R., Fahim, Z., Ansari, M. A., Aimen, S., et al. (2025) · Journal of Central Nervous System Disease · doi:10.1177/11795735251388781 · Cited by 12
Fecal microbiota transplantation for Parkinson's disease: A systematic review of clinical evidence
Shekar, S., Venkatachalapathy, R., Jayaraman, A., & Siddhu, N. S. S. (2025) · Medicine in Microecology · doi:10.1016/j.medmic.2025.100128 · Cited by 10
The microbiota-brain connection in neurological diseases: the ubiquitous short-chain fatty acids
Bertin, L., Bonazzi, E., Facchin, S., Lorenzon, G., Maniero, D., BARBA, C. D., Tomasulo, A., FORTUNA, A., Zingone, F., Barberio, B., et al. (2025) · Minerva Gastroenterology · doi:10.23736/s2724-5985.25.03866-5 · Cited by 10
Gut bacteria-derived metabolites and their implications in mental health and neurological diseases
Srivastava, R., & Gupta, M. K. (2025) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-025-04656-5 · Cited by 10
Faecal microbiota transplant for Parkinson’s disease: promises and future directions
Tan, E. K., Wang, J. D. J., Pettersson, S., Wang, Q., Takahashi, R., Poewe, W. H., Jankovic, J. J., & Rascol, O. (2025) · Brain · doi:10.1093/brain/awaf419 · Cited by 10
Culqui, D. R., Sanz, P. R., Sanchez, R. P., Miranda, M. Y. S., Cruz-López, C. Y. S., & Rodríguez, J. A. M. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.08.003 · Cited by 9
Subramanian, I., Ricciardi, L., Schrag, A. E., Appel‐Cresswell, S., Kola, S., Domingos, J., Pickut, B. A., Dahodwala, N. A., Bocoum, A., Falup‐Pecurariu, C., et al. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70381 · Cited by 9
Chakif, D., & Furrer, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1765786 · Cited by 9
Bertoni, G., Ristori, S., & Monti, D. (2026) · Cells · doi:10.3390/cells15080657 · Cited by 10
Advice to People with Parkinson’s in My Clinic: Probiotics and Prebiotics
Hor, J. W., Toh, T. S., Lim, S., & Tan, A. H. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240172 · Cited by 9
Fecal Microbiome Transplants For Parkinson Disease
Sampson, T. R. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2293 · Cited by 8
Morais, L. H., Stiles, L., Freeman, M., Oguienko, A. D., Hoang, J. D., Ji, J., Jones, J. J., Quan, B., Devine, J., Bois, J. S., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01142-5 · Cited by 9
Matera, M., Biagioli, V., Illiceto, M. T., Palazzi, C. M., Cavecchia, I., Manzi, A., Lugli, S., Pennazzi, L., Meocci, M., Pedaci, F. A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1726630 · Cited by 7
Moiseyenko, A., Antonello, G., Schonhoff, A. M., Boktor, J. C., Long, K., Dirks, B., Oguienko, A. D., Winnett, A. V., Simpson, P., Daeizadeh, D., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01287-x · Cited by 8
The role of the gut microbiome in Parkinson’s disease
Metcalfe‐Roach, A., & Finlay, B. B. (2025) · Future Neurology · doi:10.1080/14796708.2025.2494981 · Cited by 6
Microbial diversity in drug-naïve Parkinson’s disease patients
Papić, E., Rački, V., Hero, M., Zimani, A. N., Sajko, M. Č., Rožmarić, G., Čizmarević, N. S., Ostojić, S., Kapović, M., Hauser, G., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328761 · Cited by 6
Developing personalized treatment strategies for Parkinson’s disease based on disease subtypes
Hey, G. E., Eisinger, R. S., Guarín, D. L., Safarpour, D., Rodríguez‐Violante, M., & Ramirez‐Zamora, A. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2552784 · Cited by 7
Beckers, M., Coburn, B. A., Kalia, L. V., & Bloem, B. R. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-249007 · Cited by 6
Allani, M., Nath, G., Juyal, G., Joshi, M. C., & Tiwari, V. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108275 · Cited by 5
Chi, F., Chen, K., Yin, Y., Hakovirta, J. R., & Saris, P. E. J. (2026) · Sustainable Microbiology · doi:10.1093/sumbio/qvag002 · Cited by 5
Ma, C., Wen, H., Wenhao, Y., Changqing, L., Li, C., & Zhao, X. (2024) · Brain and Behavior · doi:10.1002/brb3.70169 · Cited by 5
Alpha-Synuclein Dysregulation in Systemic Pathophysiology of Synucleinopathies
Dolin, H. H., Zhou, B., & Maitta, R. W. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl27178 · Cited by 5
Research progress on natural products in regulating the gut microbiota in Parkinson’s disease
Jia, Y., Zhang, Y., Tai, X., Zhao, T., Zhang, H., & Zhou, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1667694 · Cited by 4
Zhao, Z., Dong, M., Mu, Z., ZHENG, Z., & ZHANG, Z. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101521 · Cited by 4
Advances and challenges in microbiome transplantation
Sen, P., Kaulmann, D., Youngster, I., Abdeen, S. K., & Elinav, E. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.06.006 · Cited by 4
Gut microbiota in health and disease
Li, Y. N., Xiao, X., Jiang, X., Li, X., WANG, W., & Lin, R. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00512-6 · Cited by 6
Parkinson’s gut-microbiota links raise treatment possibilities
DeWeerdt, S. (2025) · Nature · doi:10.1038/d41586-025-01253-2 · Cited by 4
Koros, C., Fiske, B. K., & Stefanis, L. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251354935 · Cited by 3
Iyengar, A. S., Dunkley, P. R., & Dickson, P. W. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578755 · Cited by 3
Therapeutic role of probiotics in motor and non-motor symptoms of Parkinson’s disease
Páez‐García, S., Hernández-Triana, D., Salazar, F. E., Barreto, G. E., Rodríguez-Oroz, M. C., & Borda, M. G. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2025.1004129 · Cited by 3
Figliomeni, A., Winter, S. J., Abonnel, M. Y., Kenna, J. E., Lodge, S., Whiley, L., Bernal, A., Coudert, J. D., Noonan, J. E., Kaskow, B. J., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01212-8 · Cited by 3
Geremamo, Y. D., Hasan, A., Razzak, S. A., & Uddin, S. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126604 · Cited by 3
McCafferty, C. E., Townsend, J. O., Bacchi, S., & Jensen, S. O. (2026) · Journal of Hospital Infection · doi:10.1016/j.jhin.2026.01.017 · Cited by 3
Gut–Brain Signaling in Parkinson’s Disease: A Narrative Review
Ratajczyk, K. J., Kaczorowska, E., Wyka, K., Tarasiuk, A., Fichna, J., & Gajos, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083531 · Cited by 3
The 2024 yearbook of Neurorestoratology
Huang, H., Sanberg, P. R., Sharma, H. S., Bach, J. R., Saberi, H., Shetty, A. K., Otom, A. H., Ramón‐Cueto, A., Kuffler, D., Guo, X., et al. (2025) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2025.100250 · Cited by 4
Parkinson’s Disease and the faecal microbiota transplantation. Review of current knowledge
Dudek, M., Silldorff, J., Zajac, M., Fura, T., Felińska, Z., Anczyk, S., Iszczuk, O., Gajkiewicz, M., & Zaucha, R. (2024) · Quality in Sport · doi:10.12775/qs.2024.21.54082 · Cited by 2
Takeshige‐Amano, H., Igami, E., Okuzumi, A., Kamo, R., Iseki, M., Tsuyama, K., Wakamori, R., Okada, H., Taniguchi, D., Ueno, S., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-102851 · Cited by 2
Zhang, Y., Chen, L., Jin, J., Xin, Y., Wang, J., & Zhang, A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115631 · Cited by 2
Silent Intruders: The Gut Virome in Brain Aging and Cognitive Decline
Silvestro, S., Midiri, A., Biondo, C., Casilli, S., Borrello, L., Zummo, S., & Mancuso, G. (2026) · Pathogens · doi:10.3390/pathogens15020180 · Cited by 2
How to set up and manage a microbiome research facility
Henderickx, J. G. E., Smits, W. K., Zeller, G., & Kuijper, E. J. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.02.007 · Cited by 2
Targeting TLR4 in Parkinson's disease: mechanisms and therapeutic prospects
Dong, S., Lu, J., Wu, L., Wang, S., 宫玉波, Hu, J., Liu, Y., & Chen, X. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116780 · Cited by 2
Jadhav, V. S., Nathiya, D., Tomar, B. S., & Khatri, D. K. (2026) · Discover Immunity. · doi:10.1007/s44368-026-00029-8 · Cited by 2
Rationale and current status of fecal microbiota transplantations for Parkinson's disease
Bruggeman, A., Vandenbroucke, R. E., & Santens, P. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261455608 · Cited by 2
Self-citationBajić, D., Vučković, J., Pupovac, N., Slavić, D., Stojsic, M., Hodoba, N., Todorović, N., Plazačić, M., & Milosevic, N. P. (2026) · Medical Sciences · doi:10.3390/medsci14050536 · Cited by 1
Prajapati, C., Nand, S., Parmar, G. R., & Singh, S. K. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-95-2104-3_14 · Cited by 1
Reinventing brain immunity in neurodegeneration
Huang, H., Han, Y., Han, Z., Yang, H., Fu, Y., & Liu, Q. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00011-3 · Cited by 1
Fecal Microbiota Transplantation in Parkinson Disease
Pereira, M. A. O. M., Tudella, G. C. N., Klostermann, A. U., Ohannesian, V. A., Gonçalves, O. R., da Silva, R. O., Fernandes, J. V. A., Ahmed, A., Alencar, A. B., de Morais, S. T. A., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218175 · Cited by 1
Siam, A. M., Moubarak, E. S., Mahmoud, N.-E., Khelifa, H., Aljalawy, F., Hassan, A. A., Ahmed, N. A. T., Wagdy, M., Heikal, Y., & Abbas, O. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09274-z · Cited by 1
Metadata
- Authors
- Bruggeman, A., Vandendriessche, C., Hamerlinck, H., De Looze, D., Tate, D. J., Vuylsteke, M., De Commer, L., Devolder, L., Raes, J., Verhasselt, B., Laukens, D., Vandenbroucke, R. E., & Santens, P.
- Affiliations
- Ghent University Hospital (BE)
- Ghent University (BE)
- VIB-UGent Center for Inflammation Research (BE)
- Rega Institute for Medical Research (BE)
- Corresponding author
- Santens, Patrick
- ORCID
- Venue
- eClinicalMedicine
- Publisher
- Elsevier BV
- Published
- 2024-05
- Volume
- 71
- Pages
- 102563
- ISSN
- 2589-5370 (ISSN-L)
- PMC
- PMC11056595
- OpenAlex
- W4393224953
- Cited by
- 139
- References
- 32
- Citations by year
- 2026: 48 · 2025: 71 · 2024: 20
- FWCI
- 37.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- EClinicalMedicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by-nc-nd)
- Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Biocodex Microbiota Foundation
- Fonds Wetenschappelijk Onderzoek (1295223N, T000819N)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, Parkinson's disease, early-stage Parkinson's disease, gut microbiota, motor symptoms, treatment safety, adverse events, microbiota-based therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
